FIRST-NEC (GFPC 01-2022): A multicenter phase II study evaluating the efficacy and safety of the combination of durvalumab with etoposide and platinum as first line treatment in patients with advanced large-cell neuroendocrine lung carcinomas (LCNECs).
Year: 2025
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Dominique Arpin, Julien Gautier, Audrey Mansuet-Lupo, Romain Corre, Aymeric De Monfort, Sylvie Chabaud, Chantal Decroisette Phan Van Ho, Sébastien Couraud, Marie Wislez, Simonneau Yannick, Solene Chaleat, Charles Ricordel, Anne Claire Toffart, Didier Debieuvre, Ivana Sondarjee, Jean-Bernard Auliac, Diane Damotte, Laurent Greillier, David Pérol, Luc Odier
Institutions: Centre Léon Bérard, Université Paris Cité, Hôpital Cochin, Assistance Publique – Hôpitaux de Paris, Centre Hospitalier de Cornouaille, Hospices Civils de Lyon, Hôpital Lyon Sud, Hôpital Universitaire Dupuytren, Centre Hospitalier Intercommunal Aix-Pertuis, Centre Hospitalier Universitaire de Rennes, Hôpital Albert Michallon, Groupe Hospitalier de la Région de Mulhouse et Sud Alsace, Aix-Marseille Université, Assistance Publique Hôpitaux de Marseille
Language: English
Topic: Lung Cancer Research Studies
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4410804473